sovereign 02, one of the anti-Covid-19 vaccines created by Cuban scientistswill be able to have its final production in Italy thanks to an agreement signed this Thursday by the Finlay Institute of Vaccines (IFV) and the Italian-Swiss company Adienne, according to official media on the island.
The signing of the document took place within the framework of the BioHabana 2022 International Congress, which is being held in the Cuban capital, and was attended by Vicente Vérez, general director of the IFV, Antonio Dinaro, president of the Adienne company, and the head of the Italian Agency for Cultural and Economic Exchange with Cuba, Michele Curto, according to a report of the Prensa Latina (PL) agency.
Vérez assured that in a first phase this alliance will allow formulating, filling and packaging the immunizer in the facilities of the company Adienne in Italyand in a second to evaluate the total manufacture of the preparation and of others designed by the IFV, specifies the medium.
Soberana 02 is specially designed for children and managed to demonstrate in clinical trials all the advantages that conjugate vaccines provide for the pediatric population, highlighted the specialist cited by PL.
Vérez explained that this product has a completed phase III and IV because it has a massive application that showed high safety, and an evaluation of the impact of that administration, which makes it a unique option in the world, adds the report.
In reference to its safety, the specialist stated that he has had all the evidence of safety, immunogenicity and efficacy for months to be used in children from 2 to 5 years of age, the report points out.
For her part, the director of IFV Research, Dagmar Herrera, clarified that in addition to the results exhibited by Soberana 02, the scientific institution showed in BioHabana 2022 the progress of the Soberana 01 vaccine candidate.
The expert clarified that Soberana 01 proved to be superior in the response induced in adults over 60 years of age and in people whose reaction to primary immunization was not as expected, according to information from PL.
“We verified that it is not inferior to Soberana 02 in its use as a vaccine in primary immunization and, in addition, thanks to a clinical trial carried out in Havana with health workers, we had evidence that it is just as good as Soberana Plus as a dose. of reinforcement”, affirmed Herrera.
The media outlet specifies that another agreement was also signed on the day between the BioCubaFarma business group, represented by its president Eduardo Martínez, and the Italian Agency for Cultural and Economic Exchange with Cuba.
This letter of intent is intended to begin a broad cooperation process and the search for alliances with Italian companies, Martínez explained at the event, which was also attended by the Italian ambassador to Cuba, Roberto Vellano, and Juan Garay, director collaboration of the European Union on the Island.
